3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
27
Magnetic Resonance Spectroscopy
23
Cyclophosphamide
16
Biopsy
16
Doxorubicin
13
pembrolizumab
11
Temozolomide
11
X-Rays
10
Radiation
10
atezolizumab
8
Radiotherapy
8
Irinotecan
8
Phantoms, Imaging
7
Nivolumab
7
fludarabine
6
Vincristine
6
Immunoglobulin G
6
Etoposide
6
Bevacizumab
6
liposomal doxorubicin
5
cemiplimab
5
cabozantinib
5
Sirolimus
5
Ifosfamide
5
Gemcitabine
5
Disulfides
5
palbociclib
4
olaparib
4
fludarabine phosphate
4
Surgical Procedures, Operative
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
SGN-LIV1A
×
Sarcoma
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled